Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA ‘black box’ warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper.

高尿酸血症和痛风与心血管 (CV) 疾病、中风、高血压、心力衰竭和慢性肾病的风险增加有关，可能是通过促炎环境。然而，并非所有用于痛风治疗的药物都能改善心血管结局。秋水仙碱已显示出改善近期心肌梗死和稳定冠状动脉疾病患者的心血管结局，而与降脂作用无关。在 COLCOT、LoDoCo、LoDoCo2、LoDoCo-MI 试验和 COLCORONA 试验发表后，人们对秋水仙碱的兴趣重新高涨，这将阐明其在 COVID-19 中的效用。我们的目的是回顾秋水仙碱在心包疾病之外的 CV 使用情况，以及现有痛风疗法（包括别嘌醇和非布司他）的 CV 结果。CARES 试验及其周围的争议，